Flucytosine

J. E. Bennett

Research output: Contribution to journalArticle

Abstract

Flucytosine is a systemic antifungal drug that is readily absorbed from the gastrointestinal tract. The most clearly documented therapeutic effect has been in cryptococcosis, candidiasis, and chromomycosis. An important limitation of the use of flucytosine in all 3 diseases has been drug resistance arising during therapy. The addition of low-dose, intravenous amphotericin B to flucytosine therapy of cryptococcosis has appeared to decrease the frequency of secondary flucytosine resistance. In addition, the 2 drugs have an additive or slightly synergistic effect against flucytosine susceptible isolates of Cryptococcus and Candida. The combination is probably the treatment of choice in cryptococcal meningitis and offers promise in the therapy of systemic candidiasis and nonmeningeal cryptococcosis.

Original languageEnglish (US)
Pages (from-to)319-322
Number of pages4
JournalAnnals of Internal Medicine
Volume86
Issue number3
StatePublished - 1977
Externally publishedYes

Fingerprint

Flucytosine
Cryptococcosis
Chromoblastomycosis
Cryptococcal Meningitis
Cryptococcus
Candidiasis
Amphotericin B
Therapeutic Uses
Candida
Drug Resistance
Pharmaceutical Preparations
Gastrointestinal Tract
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bennett, J. E. (1977). Flucytosine. Annals of Internal Medicine, 86(3), 319-322.

Flucytosine. / Bennett, J. E.

In: Annals of Internal Medicine, Vol. 86, No. 3, 1977, p. 319-322.

Research output: Contribution to journalArticle

Bennett, JE 1977, 'Flucytosine', Annals of Internal Medicine, vol. 86, no. 3, pp. 319-322.
Bennett JE. Flucytosine. Annals of Internal Medicine. 1977;86(3):319-322.
Bennett, J. E. / Flucytosine. In: Annals of Internal Medicine. 1977 ; Vol. 86, No. 3. pp. 319-322.
@article{4c5c16cb23344615a31490379ad4d6fb,
title = "Flucytosine",
abstract = "Flucytosine is a systemic antifungal drug that is readily absorbed from the gastrointestinal tract. The most clearly documented therapeutic effect has been in cryptococcosis, candidiasis, and chromomycosis. An important limitation of the use of flucytosine in all 3 diseases has been drug resistance arising during therapy. The addition of low-dose, intravenous amphotericin B to flucytosine therapy of cryptococcosis has appeared to decrease the frequency of secondary flucytosine resistance. In addition, the 2 drugs have an additive or slightly synergistic effect against flucytosine susceptible isolates of Cryptococcus and Candida. The combination is probably the treatment of choice in cryptococcal meningitis and offers promise in the therapy of systemic candidiasis and nonmeningeal cryptococcosis.",
author = "Bennett, {J. E.}",
year = "1977",
language = "English (US)",
volume = "86",
pages = "319--322",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "3",

}

TY - JOUR

T1 - Flucytosine

AU - Bennett, J. E.

PY - 1977

Y1 - 1977

N2 - Flucytosine is a systemic antifungal drug that is readily absorbed from the gastrointestinal tract. The most clearly documented therapeutic effect has been in cryptococcosis, candidiasis, and chromomycosis. An important limitation of the use of flucytosine in all 3 diseases has been drug resistance arising during therapy. The addition of low-dose, intravenous amphotericin B to flucytosine therapy of cryptococcosis has appeared to decrease the frequency of secondary flucytosine resistance. In addition, the 2 drugs have an additive or slightly synergistic effect against flucytosine susceptible isolates of Cryptococcus and Candida. The combination is probably the treatment of choice in cryptococcal meningitis and offers promise in the therapy of systemic candidiasis and nonmeningeal cryptococcosis.

AB - Flucytosine is a systemic antifungal drug that is readily absorbed from the gastrointestinal tract. The most clearly documented therapeutic effect has been in cryptococcosis, candidiasis, and chromomycosis. An important limitation of the use of flucytosine in all 3 diseases has been drug resistance arising during therapy. The addition of low-dose, intravenous amphotericin B to flucytosine therapy of cryptococcosis has appeared to decrease the frequency of secondary flucytosine resistance. In addition, the 2 drugs have an additive or slightly synergistic effect against flucytosine susceptible isolates of Cryptococcus and Candida. The combination is probably the treatment of choice in cryptococcal meningitis and offers promise in the therapy of systemic candidiasis and nonmeningeal cryptococcosis.

UR - http://www.scopus.com/inward/record.url?scp=0017579803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017579803&partnerID=8YFLogxK

M3 - Article

VL - 86

SP - 319

EP - 322

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 3

ER -